Journal of Neurology, Journal Year: 2024, Volume and Issue: 271(7), P. 3879 - 3896
Published: May 21, 2024
Language: Английский
Citations
6Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG–Positive NMOSD
Neurology, Journal Year: 2024, Volume and Issue: 103(12)
Published: Nov. 19, 2024
In aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed assess the prevalence of progression independent relapse activity (PIRA) and relapse-associated worsening (RAW) in AQP4-IgG NMOSD. was a retrospective cohort patients with NMOSD enrolled MSBase international data registry. Patients required minimum 3 recorded Expanded Disability Status Scale (EDSS) scores: baseline, event, 6-month confirmation score. Presence absence relapses between baseline event EDSS scores determined RAW PIRA, respectively. Descriptive statistics were used present results. A total 181 followed for median 4.5 years (Q1 1.7, Q3 7.8) included. Most female (88.4%), age at disease onset 38.1 years. Overall, 4 (2.2%) developed 5 incidences PIRA 13 (7.2%). multicenter highlights that very rare Limitations this include sole focus overall measure disability, lack requirement second score confirm EDSS, magnetic resonance imaging information all patients.
Language: Английский
Citations
5Blood–Brain Barrier Disruption in Neuroimmunological Disease
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10625 - 10625
Published: Oct. 2, 2024
The blood–brain barrier (BBB) acts as a structural and functional for brain homeostasis. This review highlights the pathological contribution of BBB dysfunction to neuroimmunological diseases, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), autoimmune encephalitis (AE), paraneoplastic neurological syndrome (PNS). transmigration massive lymphocytes across caused by activation cell adhesion molecules is involved in early phase MS, cortical associated with atrophy gray matter late MS. At onset NMOSD, increased permeability causes entry circulating AQP4 autoantibodies into central nervous system (CNS). Recent reports have shown importance glucose-regulated protein (GRP) BBB-reactive which induce antibody-mediated dysfunction. breakdown has also been observed MOGAD, NPSLE, AE anti-NMDAR antibodies. Our recent report demonstrated presence GRP78 patients MOGAD molecular mechanism responsible autoantibody-mediated impairment. Disruption may explain symptoms cerebellum development PNS, it induces pathogenic or CNS through autoimmunity against tumors periphery. were detected cerebellar degeneration Lambert–Eaton myasthenic syndrome, they ataxia anti-P/Q type voltage-gated calcium channel that therapies affecting are currently available disease-modifying diseases potential prevent damage.
Language: Английский
Citations
4Cognitive disorders in patients with neuroimmunological disease
Current Opinion in Psychiatry, Journal Year: 2025, Volume and Issue: 38(2), P. 126 - 133
Published: Jan. 24, 2025
Purpose of review Autoimmune diseases such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), and autoimmune encephalitis can directly indirectly affect brain function, leading to cognitive dysfunction or well characterized neurocognitive syndromes. However, these are often poorly in the literature. Here, we evidence on clinical manifestations, risk factors, their assessment outcomes, for underlying mechanisms associated biomarkers, if available. Recent findings Significant advances have been made disorders with four categories disease: due connective tissue diseases, demyelinating CNS, encephalitis, cerebrovascular disease origin. Summary should be considered critical causal factors new cases disorder, especially young patients. These mediated by immune system reactions involving antibody production, T-cell-mediated damage, demyelination. Although prognosis seems favourable most conditions after immunotherapy, magnitude therapeutic effect immunotherapy functioning remains unclear.
Language: Английский
Citations
0Exploring core symptoms and symptom clusters among patients in neuromyelitis optica spectrum disorder: A network analysis
International Journal of Nursing Sciences, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
0Is a Benign Disease Course Possible in Untreated
European Journal of Neurology, Journal Year: 2025, Volume and Issue: 32(3)
Published: March 1, 2025
ABSTRACT Background Most patients with aquaporin‐4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4‐IgG NMOSD) require life‐long immunosuppression to prevent relapses. Patients who are untreated or undergo de‐escalation of therapy typically experience severe disabling We present a series who, despite not receiving immunosuppression, developed minimal disability. Methods Case from UK national NMOSD referral centre. defined benign disease as an estimated disability status scale score ≤ 3 after minimum 4 years without immunotherapy. Results Of 153 AQP4‐IgG patients, 8 (5.2%) had course median follow‐up 7.5 (Q1: 5.8, Q3: 13.3) All were female, and 7/8 White racial background. Clinical attacks included isolated optic neuritis, transverse myelitis, area postrema syndrome combinations these syndromes. Conclusion The presence the potential for safe in remains unclear. This study suggests that both may be possible. Further studies similar cases could provide valuable insights identify biomarkers treatment discontinuation.
Language: Английский
Citations
0Nanomaterials as Novel Matrices to Improve Biomedical Applications of MALDI-TOF/MS
Talanta, Journal Year: 2025, Volume and Issue: unknown, P. 128092 - 128092
Published: April 1, 2025
Language: Английский
Citations
0Microglia/Macrophages in Autoimmune Demyelinating Encephalomyelitis (Multiple Sclerosis/Neuromyelitis Optica)
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3585 - 3585
Published: April 10, 2025
Microglia and macrophages are critical mediators of immune responses in the central nervous system. Their roles range from homeostatic maintenance to pathogenesis autoimmune demyelinating diseases such as multiple sclerosis neuromyelitis optica spectrum disorder. This review explores origins microglia macrophages, well their mechanisms activation, interactions with other neural cells, contributions disease progression repair processes. It also highlights translational relevance insights gained animal models therapeutic potential targeting microglial macrophage activity
Language: Английский
Citations
0Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study
Journal of Neurology, Journal Year: 2025, Volume and Issue: 272(5)
Published: April 14, 2025
Language: Английский
Citations
0Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives
Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 85, P. 105559 - 105559
Published: March 19, 2024
Language: Английский
Citations
3